A randomized, double-blind, placebo-controlled, dose ranging study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK221149A administered intravenously in healthy, pregnant females, with uncomplicated preterm labor between 30 0/7 - 35 6/7 weeks gestation.
Phase of Trial: Phase II
Latest Information Update: 19 Jul 2011
At a glance
- Drugs Retosiban (Primary)
- Indications Preterm labour
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 19 Jul 2011 New trial record